The presence of the BCR-ABL1 fusion gene as a pathognomonic molecular event in almost all the CML cases has distinguished this malignancy from other myeloproliferative disorders. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.